Inside the UK’s campaign to reschedule psilocybin with MP Crispin Blunt
UK Member of Parliament Crispin Blunt has championed the campaign to reschedule psilocybin for scientific and research purposes. Last month the honourable Mr Blunt raised the issue directly with Boris Johnson at Prime Minister’s Questions, with Johnson declaring he would get back to Blunt at the earliest opportunity.
This elevated the campaign to national headlines, and a week later COMPASS Pathways released data from its pivotal Phase IIb trial, which demonstrated psilocybin’s efficacy in treatment-resistant depression.
PSYCH sat down with Blunt and Timmy Davis, Psilocybin Rescheduling Project Manager at the Conservative Drug Policy Reform Group, to discuss the groundbreaking study and the future of the nation’s psychedelic healthcare industry.
Read More